AbCellera - Positive Top-Line Phase 2 Results for ABCL635 (Aug 10, 2026)
Tier 1: Established: peer-reviewed research or government health authority
Publisher: AbCellera Biologics Inc. · Published: August 10, 2026 ·
Accessed: August 14, 2026
Visit the source ↗
Claims this source supports
- On August 10, 2026, AbCellera announced positive top-line Phase 2 clinical trial results for ABCL635, demonstrating a significant reduction in the frequency and severity of vasomotor symptoms and a favorable tolerability profile (company announcement headline).
- ABCL635 is an investigational first-in-class antibody medicine for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes) due to menopause; it specifically targets NK3R, a protein found on KNDy neurons in the infundibular nucleus of the hypothalamus that help regulate body temperature.
- ABCL635 is administered by subcutaneous injection and is designed with the potential for once-monthly self-injection, efficacy comparable to small molecules, and a differentiated safety profile without the need for liver enzyme monitoring (company pipeline positioning, not yet proven in Phase 3).
- It is currently being studied in a Phase 1/2 trial evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and the frequency and severity of vasomotor symptoms.
- On August 11-12, 2026, AbCellera announced and priced an oversubscribed $200 million public offering of common shares and pre-funded warrants.